Long Term Disease Control of Brain Metastases From Chemotherapy‐Resistant Endometrial Cancer With Lenvatinib and Pembrolizumab: A Case Report

TL;DR

A patient with chemotherapy-resistant endometrial cancer brain metastases showed long-term improvement with lenvatinib and pembrolizumab.

Contribution

Demonstrates effectiveness of lenvatinib plus pembrolizumab in treating rare brain metastases from endometrial cancer.

Findings

Combination therapy achieved sustained partial remission for 16 months without brain hemorrhage.

Treatment was effective in a chemotherapy-resistant case with no extracranial involvement.

Outcome challenges poor prognosis and suggests novel strategies for this rare condition.

Abstract

Brain metastases from endometrial carcinoma are extremely rare and associated with poor prognosis. We present a 43‐year‐old woman with mismatch repair deficient endometrial cancer who developed multiple brain metastases refractory to cytotoxic chemotherapy and without extracranial involvement. After stereotactic radiotherapy, combination therapy with lenvatinib and pembrolizumab resulted in sustained partial remission for 16 months, with no evidence of brain hemorrhage. This case demonstrates that lenvatinib plus pembrolizumab may offer an effective and safe therapeutic option for brain metastases from endometrial cancer, even in patients resistant to conventional therapy. Remarkably, this outcome challenges the traditionally poor prognosis of such cases and underscores the potential for novel targeted and immunotherapeutic strategies to redefine the standard of care for this rare and devastating complication.

Figures